Home » Topics » Disease categories and therapies » Dental

Dental
RSS

Acacia Pharma initiates phase II study of locally administered xerostomia drug

July 25, 2011

PMX-30063 shows activity against oral mucositis in animal study

May 24, 2011

Septodont acquires local anesthesia reversal agent OraVerse from Novalar

March 21, 2011

Acacia Pharma completes phase I APD-515 trial for xerostomia in advanced cancer

Feb. 16, 2011

Oragenics plans second phase I trial of SMaRT replacement therapy

Feb. 2, 2011

Strativa launches Oravig in U.S. for oropharyngeal candidiasis

Aug. 25, 2010

Access Pharma and BioScrip sign MuGard distribution agreement

July 22, 2010

Sanofi-aventis and Novalar submit OraVerse MAA in five European countries

July 16, 2010

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

April 20, 2010

BioDelivery Sciences presents update on BEMA Buprenorphine

March 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...